secwatch.observer — SEC 8-K summary
======================================

Issuer:     HeartSciences Inc. (HSCS)
CIK:        0001468492
Form:       8-K
Filed at:   2025-09-11T23:59:59+00:00
Accession:  0001468492-25-000011
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HeartSciences reports Q1 FY2026 with $2.8M cash; launches MyoVista Insights platform
--------------------------------------------------------------------------------

- No meaningful revenue for Q1 FY2026; cash and equivalents $2.8M, shareholders' equity $3.1M as of July 31, 2025.
- Post-quarter raised $0.8M via Reg A+ and exchanged $0.7M debt into equity, strengthening balance sheet.
- FDA granted Breakthrough Device designation for aortic stenosis ECG algorithm; now holds 44 granted patents.
- Launched MyoVista Insights cloud-native platform; phased rollout began May 2025.
- Separate FDA submissions planned for MyoVista wavECG device and algorithm, targeting clearances in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468492/000146849225000011/0001468492-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468492/000146849225000011/hscs-20250911.htm
  HTML page:      https://secwatch.observer/filing/0001468492-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer